Summary
The efficacy and toxicity of 120 mg/m2 etoposide and 100 mg/m2 carboplatin given i.v. daily x 3 together with 750 mg/m2 cyclophosphamide and 14 mg/m2 vincristine given i.v. on day 1 (ECCO) in a regimen given every 28 days for 6 courses was assessed in 90 (40 limited stage, 50 extensive stage) previously untreated patients with small-cell lung cancer. Mediastinal irradiation using 50 Gy in 25 fractions was given to limitedstage patients without progression after 3 courses of chemotherapy. Cranial irradiation with 30 Gy in 10 fractions was given to all patients attaining a complete response (CR). Objective responses were seen in 83% [CR, 60%; partial response (PR), 23%] of patients with limited and 76% (CR, 22%; PR, 54%) of those with extensive disease. The median relapse-free survival for objective responders with limited disease was 13.4 months, with a median of 8.0 months for extensive-stage patients. The median relapse-free survival for patients achieving a CR was 13.4 months, with a median of 7.8 months for those undergoing a PR. The median survival was 13.3 months for patients with limited disease, with a median of 9.6 months for those with extensive disease. The median survival following a CR was 18.2 months, with a median survival of 9.9 months for those showing a PR. The combination was well tolerated, with either no nausea or nausea only (WHO grade 0 or 1) in 56% of patients and minimal mucositis, renal toxicity, neurotoxicity or ototoxicity. Neutropenia measuring <1.0×109 WBC/l (WHO grade 3 or 4) was seen in 74% of patients, with two deaths due to infection occurring during neutropenia. Thrombocytopenia of <50×109 platelets/l (WHO grade 3 or 4) occurred in 24% of patients. ECCO is a new, active, welltolerated program for previously untreated patients with small-cell lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bishop JF, Raghavan D, Stuart-Harris R, Morstyn G, Aroney R, Kefford R, Yuen K, Lee J, Giantoutsos P, Olver IN, Zalcberg J, Ball D, Bull C, Fox R (1987) Carboplatin (CBDCA JM-8) and VP16-213 in previously untreated patients with small cell lung cancer. J Clin Oncol 5 (10): 1574–1578
Canetta R, Rozencweig M, Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 [Suppl A]: 125–136
Cavalli F, Goldhirsch A, Siegenthaler P, Kaplan S, Beer M (1980) Phase II study withcis-dichlorodiammineplatinum(II) in small cell anaplastic bronchogenic carcinoma. Eur J Cancer 16: 617–621
Dixon WJ (ed) (1981) BMDP statistical software 1981. University of California, Berkeley, pp 557–575
Dombernowski P, Sorenson S, Aisner J, Hansen HH (1979)cis-Dichlorodiammineplatinum(II) in small cell anaplastic bronchogenic carcinoma: a phase II study. Cancer Treat Rep 63: 543–545
Egorin MJ, Van Echo DA, Tipping SJ (1984) Pharmacokinetics and dosage reductions ofcis-diammine(1,1-cyclobutanedecarboxylato)platinum in patients with impaired renal function. Cancer Res 44: 5432–5438
Evans WK, Osobe D, Feld R, Shepherd FA, Bagos MJ, DeBoer G (1985) Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small cell lung cancer. J Clin Oncol 3 (1): 65–71
Evans WK, Feld P, Murray N (1987) Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. Ann Intern Med 107: 451–458
Harrap KR, Jones M, Wilkinson CR (1980) Antitumour, toxic and biochemical properties of cisplatin and eight other platinum complexes. In: Prestayko AW, Cook ST, Carter SK (eds) Cisplatin, current status and new developments. Academic, New York, pp 193–212
Lelireld P, Van der Vijgh WJF, Veldhuizen RW (1984) Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer 20:1087–1103
Livingston RB, Stephens RL, Bonnet JD, Grozea PN, Lehane DE (1984) Long-term survival and toxicity in small cell lung cancer. Am J Med 177: 415–417
Maurer LH, Pajak T, Eaton W (1985) Combined modality therapy with radiotherapy, chemotherapy and immunotherapy in limited small-cell carcinoma of the lung: a phase III Cancer and Leukemia Group B study. J Clin Oncol 3: 969–976
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214
Morstyn G, Ihde DC, Lichter AS (1984) Small cell lung cancer 1973–1983: early progress and recent obstacles. Radiol Oncol Biol Phys 10 (4):515–539
Roswitt B, Patno ME, Rapp R (1968) The survival of patients with inoperable lung cancer: a large scale randomized study of radiation therapy versus placebo. Radiology 90: 688–697
Rozencweig M, Nicaise C, Beer M (1983) Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol 1: 621–626
Sierocki JS, Hilaris BS, Hopfan S, Martini V, Barton D, Gobey RB, Wittes RE (1979)cis-dichlorodiammine-platinum(II) and VP16-213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63 (9–10): 1593–1597
Smith IE, Harland SJ, Robinson BA (1985) Carboplatin: a very active new cisplatin analogue in the treatment of small cell lung cancer. Cancer Treat Rep 69: 43–46
Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT (1987) Carboplatin (Paraplatin, JM-8) and etoposide (VP16) as first line combination therapy for small cell lung cancer. J Clin Oncol 5 (2): 185–189
Wiltshaw E (1985) Ovarian trials at the Royal Marsden. Cancer Treat Rev 12 [Suppl A]: 67–71
Author information
Authors and Affiliations
Additional information
This study was partly supported by David Bull Laboratories, Melbourne, and the Anti-Cancer Council of Victoria
Rights and permissions
About this article
Cite this article
Bishop, J.F., Kefford, R., Raghavan, D. et al. Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer. Cancer Chemother. Pharmacol. 25, 367–370 (1990). https://doi.org/10.1007/BF00686239
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686239